New hope for prostate cancer: adding surgery or radiation to drug therapy may delay progression

NCT ID NCT05649943

Recruiting now Disease control Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 27 times

Summary

This study is for men with metastatic hormone-sensitive prostate cancer that has spread to a limited number of sites. Participants first receive standard drug therapy (apalutamide plus hormone therapy) for 6 months, then are randomly assigned to either continue drug therapy alone or also receive local treatment (radiotherapy or surgery to the prostate). The goal is to see if adding local treatment delays cancer progression. About 566 men from Italy will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ASST Santi Paolo e Carlo
NOT_YET_RECRUITING

Milan, Lombardy, 20153, Italy

Contact Email: •••••@•••••

Contact
European Institute of Oncology
NOT_YET_RECRUITING

Milan, Lombardy, 20141, Italy

Contact Email: •••••@•••••

Contact
Istituto Tumori Milano
RECRUITING

Milan, Mi, 20156, Italy

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)